{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang X"],"funding":["National Key R&amp;D Program of China","The project of health commission of Sichuan province","The projects of of Chengdu Science and Technology Bureau","The project of Sichuan Science and Technology Bureau"],"pagination":["128"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7425167"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(1)"],"pubmed_abstract":["<h4>Background</h4>Bempedoic acid is an oral, once-daily, first-in-class drug being developed for the treatment of hyperlipidemia. However, evidence of bempedoic acid use for the prevention of cardiovascular events and diabetes is lacking. Thus, we aim to evaluate the benefit and safety of bempedoic acid use for the prevention of cardiovascular events and diabetes.<h4>Methods</h4>We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials with no language restriction from inception until March 3, 2020. Pairs of reviewers independently identified randomized controlled trials comparing the use of bempedoic acid with placebo or no treatment for primary prevention of cardiovascular events in statin-intolerant patients with hypercholesterolemia. The primary outcomes were"],"journal":["Cardiovascular diabetology"],"pubmed_title":["Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis."],"pmcid":["PMC7425167"],"funding_grant_id":["2017SZ0142","2015-HM01-00482-SF","2020YFS0490","19PJ003","2018YFA0108604"],"pubmed_authors":["Zhou L","Wang P","Chong W","Tan H","Zhang Y","Fang F","Wang X","Zha X"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis.","description":"<h4>Background</h4>Bempedoic acid is an oral, once-daily, first-in-class drug being developed for the treatment of hyperlipidemia. However, evidence of bempedoic acid use for the prevention of cardiovascular events and diabetes is lacking. Thus, we aim to evaluate the benefit and safety of bempedoic acid use for the prevention of cardiovascular events and diabetes.<h4>Methods</h4>We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials with no language restriction from inception until March 3, 2020. Pairs of reviewers independently identified randomized controlled trials comparing the use of bempedoic acid with placebo or no treatment for primary prevention of cardiovascular events in statin-intolerant patients with hypercholesterolemia. The primary outcomes were","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2025-04-19T00:42:29.485Z","creation":"2020-08-19T07:11:58Z"},"accession":"S-EPMC7425167","cross_references":{"pubmed":["32787939"],"doi":["10.1186/s12933-020-01101-9"]}}